Literature DB >> 1889868

Interaction between HDV and HBV infection in HBsAg-chronic carriers.

E Sagnelli1, F M Felaco, M Rapicetta, T Stroffolini, A Petruzziello, T Annella, P Chionne, G Pasquale, P Filippini, P Peinetti.   

Abstract

We studied the interaction between HBV and HDV infection in 149 consecutive subjects with HBsAg positive chronic hepatitis and in 22 chronic HBsAg healthy carriers. Liver HBcAg was detected in 52 (30.4%) of the 171 subjects. Of these 52, 35 were HBV-DNA and HBeAg positive, 11 HBV-DNA positive only; two HBeAg positive only and four were negative for both HBeAg and HBV-DNA. None of the 119 HBcAg-negative subjects had detectable HBV-DNA in serum. HD-Ag in hepatocytes was detected in 31 of the 171 subjects (18%); it was detectable in none of the 22 HBsAg healthy carriers, in four of the 56 patients with chronic persistent hepatitis (7.2%), in six of the 24 patients with chronic lobular hepatitis (25%), in 16 of the 40 patients with chronic active hepatitis (40%) and in five of the 29 with cirrhosis (17%). A presence of anti-HD in serum in the absence of liver HD-Ag was found in 54 of the 171 subjects (32%). This condition was observed not only in patients with a progressive disease (37.7% of chronic active hepatitis or cirrhosis and 33% of chronic lobular hepatitis), but also in healthy carriers (36%) and in chronic persistent hepatitis patients (21.4%). Liver HBcAg was detected in 6.4% of the 31 HD-Ag-positive patients, in 12.9% of the 54 HD-Ag-negative/anti-HD positive, but in 50% of the 86 with no marker of HDV infection. HDV appears to inhibit HBV genome and such inhibition may persist even when anti-HD is the only HDV marker detectable.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1889868     DOI: 10.1007/bf01643238

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  12 in total

1.  The analysis of contingency tables with groupings based on quantitative characters.

Authors:  F YATES
Journal:  Biometrika       Date:  1948-05       Impact factor: 2.445

2.  Delta infection in hepatocellular carcinoma positive for hepatitis B surface antigen.

Authors:  G Raimondo; A Craxi; G Longo; G Giannuoli; M Caltagirone; M Aragona; G Pecoraro; G Squadrito; L Pagliaro
Journal:  Ann Intern Med       Date:  1984-09       Impact factor: 25.391

Review 3.  Experimental hepatitis delta virus infection in the chimpanzee.

Authors:  R H Purcell; W C Satterfield; K F Bergmann; A Smedile; A Ponzetto; J L Gerin
Journal:  Prog Clin Biol Res       Date:  1987

4.  Delta agent infection: an unfavourable event in HBsAg positive chronic hepatitis.

Authors:  E Sagnelli; F Piccinino; G Pasquale; M G di Costanzo; R Franzese; P Peinetti
Journal:  Liver       Date:  1984-06

5.  An improved method for HBcAg demonstration in paraffin-embedded liver tissue.

Authors:  A Trevisan; F Gudat; C Busachi; E Stöcklin; L Bianchi
Journal:  Liver       Date:  1982-12

6.  Detection of hepatitis B virus DNA in serum by a rapid filtration-hybridization assay.

Authors:  G Morace; K von der Helm; W Jilg; F Deinhardt
Journal:  J Virol Methods       Date:  1985-12       Impact factor: 2.014

7.  Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus.

Authors:  S J Hadziyannis; H M Lieberman; G G Karvountzis; D A Shafritz
Journal:  Hepatology       Date:  1983 Sep-Oct       Impact factor: 17.425

8.  Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy.

Authors:  A Smedile; C Lavarini; P Farci; S Aricò; G Marinucci; P Dentico; G Giuliani; A Cargnel; C Del Vecchio Blanco; M Rizzetto
Journal:  Am J Epidemiol       Date:  1983-02       Impact factor: 4.897

9.  Delta infection in asymptomatic carriers of hepatitis B surface antigen: low prevalence of delta activity and effective suppression of hepatitis B virus replication.

Authors:  P J Chen; D S Chen; C R Chen; Y Y Chen; H M Chen; M Y Lai; J L Sung
Journal:  Hepatology       Date:  1988 Sep-Oct       Impact factor: 17.425

10.  Long-term delta superinfection in hepatitis B surface antigen carriers and its relationship to the course of chronic hepatitis.

Authors:  M Colombo; R Cambieri; M G Rumi; G Ronchi; E Del Ninno; R De Franchis
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682

View more
  13 in total

1.  Hepatitis delta virus RNA in serum of patients with chronic delta hepatitis.

Authors:  L H Simpson; M Battegay; J H Hoofnagle; J G Waggoner; A M Di Bisceglie
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

Review 2.  Pathogenesis of and New Therapies for Hepatitis D.

Authors:  Christopher Koh; Theo Heller; Jeffrey S Glenn
Journal:  Gastroenterology       Date:  2018-10-18       Impact factor: 22.682

3.  Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection?

Authors:  Zaigham Abbas; Mustafa Qureshi; Saeed Hamid; Wasim Jafri
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485

Review 4.  Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte.

Authors:  Katja Giersch; Maura Dandri
Journal:  J Clin Transl Hepatol       Date:  2015-09-15

5.  Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome.

Authors:  Ya-Fei Guo; Jing-Xin Pan; Wei-Huang Zhuang
Journal:  Infect Agent Cancer       Date:  2018-12-12       Impact factor: 2.965

6.  Profile of HBV Integration in the Plasma DNA of Hepatocellular Carcinoma Patients.

Authors:  Weiyang Li; Xiaofang Cui; Qing Huo; Yanwei Qi; Yuhui Sun; Meihua Tan; Qingsheng Kong
Journal:  Curr Genomics       Date:  2019-01       Impact factor: 2.236

7.  Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.

Authors:  Arnolfo Petruzziello; Rocco Sabatino; Giovanna Loquercio; Annunziata Guzzo; Lucia Di Capua; Francesco Labonia; Anna Cozzolino; Rosa Azzaro; Gerardo Botti
Journal:  PLoS One       Date:  2019-02-20       Impact factor: 3.240

8.  Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam.

Authors:  Chau Le Ngoc; Thanh Tran Thi Thanh; Phuong Tran Thi Lan; Trinh Nguyen Mai; Trang Nguyen Hoa; Ngoc Nghiem My; Tan Le Van; Hung Le Manh; Phuong Le Thanh; Chau Nguyen Van Vinh; Guy Thwaites; Graham Cooke; Gabrielle M Heilek; Cecilia Shikuma; Thuy Le; Stephen Baker; Motiur Rahman
Journal:  PLoS One       Date:  2019-03-13       Impact factor: 3.240

Review 9.  Hepatitis delta virus and hepatocellular carcinoma: an update.

Authors:  Raffaella Romeo; Arnolfo Petruzziello; Eve Isabel Pecheur; Floriana Facchetti; Riccardo Perbellini; Enrico Galmozzi; Najeeb Ullah Khan; Lucia Di Capua; Rocco Sabatino; Gerardo Botti; Giovanna Loquercio
Journal:  Epidemiol Infect       Date:  2018-07-11       Impact factor: 4.434

10.  Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis.

Authors:  Ping Zhang; Qingli Liu; Mei Yuan; Lina Wang
Journal:  Infect Agent Cancer       Date:  2018-08-29       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.